R Squared’s Dyne Therapeutics DYN Stock Holding History

R Squared’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-440	Closed	-$10.4K	–	634
2024 Q4	$10.4K	Buy	+440	New	+$13K	0.01%	1141

Other funds holding DYN

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

R Squared's DYN Position: Q1 2025 in Review

R Squared sold out of Dyne Therapeutics (DYN) in Q1 2025, closing a stake of 440 shares — an estimated $10.4K sold.

R Squared first reported a position in DYN in Q4 2024 and held it in 1 quarter. The position peaked at $10.4K in Q4 2024. 205 funds tracked by Wall St. Rank hold DYN as of Q1 2025.

R Squared reported no remaining Dyne Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 440 Dyne Therapeutics shares in Q1 2025, an estimated $10.4K.
R Squared first reported a position in Dyne Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Dyne Therapeutics position peaked at $10.4K in Q4 2024.
205 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.